Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.

Nielsen MF, Wise S, Dinneen SF, Schwenk WF, Basu A, Rizza RA

Diabetes1 Dec 1997Cited by 15 (Europe PMC)

PMID9392488DOI10.2337/diab.46.12.2007PepBankPUB-09392488

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialPharmacokinetics
In diabetic and nondiabetic subjects, basal glucagon infusion produced concentrations of approximately 130 pg/ml.
In plain wordsIn diabetic and nondiabetic subjects, basal glucagon infusion produced blood concentrations of approximately 130 pg/ml.
Peptide
Glucagon
Outcome
Not applicableGlucagon concentration at basal infusion
Study
n = 19
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.65 ng x kg(-1) x min(-1)As given in this study (human).
Measurements
Glucagon concentration
≈ 130 pg/ml
basal infusion
Source sentences
Summary
On one occasion, glucagon was infused at a rate of 0.65 ng x kg(-1) x min(-1) throughout the experiment, resulting in glucagon concentrations of approximately 130 pg/ml and a slow but comparable fall in endogenous glucose production with time in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248801
02HumanNon-randomized trialPharmacokinetics
In diabetic and nondiabetic subjects, increasing glucagon infusion to 1.5 ng x kg(-1) x min(-1) raised concentrations to approximately 180 pg/ml.
In plain wordsIn diabetic and nondiabetic subjects, the lower increased glucagon dose raised blood glucagon concentrations above basal infusion levels.
Peptide
Glucagon
Outcome
IncreaseGlucagon concentration at increased infusion
Study
n = 19
Comparator
Basal infusion
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.5 ng x kg(-1) x min(-1)As given in this study (human).
Measurements
Glucagon concentration
≈ 180 pg/ml
1.5 ng x kg(-1) x min(-1)
Source sentences
Summary
On the other two occasions, the glucagon infusion was increased at 10:00 A.M. to either 1.5 or 3.0 ng x kg(-1) x min(-1), resulting in an increase in glucagon concentrations to approximately 180 and 310 pg/ml, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248802
03HumanNon-randomized trialPharmacokinetics
In diabetic and nondiabetic subjects, increasing glucagon infusion to 3.0 ng x kg(-1) x min(-1) raised concentrations to approximately 310 pg/ml.
In plain wordsIn diabetic and nondiabetic subjects, the higher increased glucagon dose raised blood glucagon concentrations above basal infusion levels.
Peptide
Glucagon
Outcome
IncreaseGlucagon concentration at increased infusion
Study
n = 19
Comparator
Basal infusion
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 ng x kg(-1) x min(-1)As given in this study (human).
Measurements
Glucagon concentration
≈ 310 pg/ml
3.0 ng x kg(-1) x min(-1)
Source sentences
Summary
On the other two occasions, the glucagon infusion was increased at 10:00 A.M. to either 1.5 or 3.0 ng x kg(-1) x min(-1), resulting in an increase in glucagon concentrations to approximately 180 and 310 pg/ml, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248803
04HumanNon-randomized trialMechanism
During glucagon infusion, the increment in endogenous glucose production did not differ between diabetic and nondiabetic subjects: 0.75 versus 0.78 mmol/kg.
In plain wordsDuring glucagon infusion, the rise in liver glucose production did not differ between diabetic and nondiabetic subjects.
Peptide
Glucagon
Outcome
No significant changeIncrement in endogenous glucose production
Study
n = 19
Comparator
Nondiabetic subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 ng x kg(-1) x min(-1)As given in this study (human).
Measurements
Glucose production increment
0.75 mmol/kg
diabetic; +/- 0.055
Glucose production increment
0.78 mmol/kg
nondiabetic; +/- 0.048
Source sentences
Summary
The increment in endogenous glucose production (i.e., area above basal) did not differ in diabetic and nondiabetic subjects during either the 1.5 ng x kg(-1) x min(-1) (0.75 +/- 0.055 vs. 0.78 +/- 0.048 mmol/kg) or 3.0 ng x kg(-1) x min(-1) (1.06 +/- 0.066 vs. 1.10 +/- 0.073 mmol/kg) glucagon infusions.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248804
05HumanNon-randomized trialMechanism
During glucagon infusion, the increment in endogenous glucose production did not differ between diabetic and nondiabetic subjects: 1.06 versus 1.10 mmol/kg.
In plain wordsDuring the higher glucagon infusion, the rise in liver glucose production did not differ between diabetic and nondiabetic subjects.
Peptide
Glucagon
Outcome
No significant changeIncrement in endogenous glucose production
Study
n = 19
Comparator
Nondiabetic subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 ng x kg(-1) x min(-1)As given in this study (human).
Measurements
Glucose production increment
1.06 mmol/kg
diabetic; +/- 0.066
Glucose production increment
1.1 mmol/kg
nondiabetic; +/- 0.073
Source sentences
Summary
The increment in endogenous glucose production (i.e., area above basal) did not differ in diabetic and nondiabetic subjects during either the 1.5 ng x kg(-1) x min(-1) (0.75 +/- 0.055 vs. 0.78 +/- 0.048 mmol/kg) or 3.0 ng x kg(-1) x min(-1) (1.06 +/- 0.066 vs. 1.10 +/- 0.073 mmol/kg) glucagon infusions.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248805
06HumanNon-randomized trialMechanism
During both increased glucagon infusions, labeled glucose release from glycogen was lower in diabetic than nondiabetic subjects.
In plain wordsDuring both increased glucagon infusions, diabetic subjects released less labeled glucose from glycogen than nondiabetic subjects.
Peptide
Glucagon
Outcome
DecreaseLabeled glucose release from glycogen
Study
n = 19
Comparator
Nondiabetic subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 and 3.0 ng x kg(-1) x min(-1)As given in this study (human).
Source sentences
Summary
In contrast, the amount of [6-3H]glucose released from glycogen was lower (P < 0.05) in the diabetic than nondiabetic subjects during both glucagon infusions.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248806
07HumanNon-randomized trialMechanism
During glucagon infusion, glycogen specific activity was lower in diabetic than nondiabetic subjects: 19.0 versus 41.4 dpm/micromol.
In plain wordsDuring glucagon infusion, glycogen specific activity was lower in diabetic than nondiabetic subjects.
Peptide
Glucagon
Outcome
DecreaseGlycogen specific activity
Study
n = 19
Comparator
Nondiabetic subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 ng x kg(-1) x min(-1)As given in this study (human).
Measurements
Glycogen specific activity
19 dpm/micromol
diabetic; +/- 3.9
Glycogen specific activity
41.4 dpm/micromol
nondiabetic; +/- 5.7
Source sentences
Summary
was lower (P < 0.05) in diabetic subjects than in nondiabetic subjects during both the 1.5 ng x kg(-1) x min(-1) (19.0 +/- 3.9 vs. 41.4 +/- 5.7 dpm/micromol) and 3.0 ng x kg(-1) x min(-1) (19.1 +/- 3.1 vs. 36.5 +/- 7.2 dpm/micromol) glucagon infusions,
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248807
08HumanNon-randomized trialMechanism
During glucagon infusion, glycogen specific activity was lower in diabetic than nondiabetic subjects: 19.1 versus 36.5 dpm/micromol.
In plain wordsDuring the higher glucagon infusion, glycogen specific activity was lower in diabetic than nondiabetic subjects.
Peptide
Glucagon
Outcome
DecreaseGlycogen specific activity
Study
n = 19
Comparator
Nondiabetic subjects
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 ng x kg(-1) x min(-1)As given in this study (human).
Measurements
Glycogen specific activity
19.1 dpm/micromol
diabetic; +/- 3.1
Glycogen specific activity
36.5 dpm/micromol
nondiabetic; +/- 7.2
Source sentences
Summary
was lower (P < 0.05) in diabetic subjects than in nondiabetic subjects during both the 1.5 ng x kg(-1) x min(-1) (19.0 +/- 3.9 vs. 41.4 +/- 5.7 dpm/micromol) and 3.0 ng x kg(-1) x min(-1) (19.1 +/- 3.1 vs. 36.5 +/- 7.2 dpm/micromol) glucagon infusions,
2 context sentences(design, population, supporting numbers)
Summary · context
To determine whether this is due to an intrinsic increase in hepatic sensitivity to glucagon, 9 NIDDM and 10 nondiabetic subjects were studied on three occasions.
Summary · context
Beginning at 6:00 A.M. on the following morning, somatostatin was infused to inhibit endogenous hormone secretion. Insulin concentrations were maintained constant at basal levels (defined as that necessary to keep glucose at approximately 5 mmol/l) in each individual.
Report a problemFND-0939248808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.